Bronchogen is a synthetic peptide of four amino acids, a tetrapeptide, designed in Russia as a tissue-specific regulator of the respiratory tract [1][12]. It belongs to the short-peptide family its inventors call peptide bioregulators: chains of two to seven amino acids studied for tissue-specific effects [12]. The idea behind the family is that such a peptide can cross the cell membrane and the nuclear envelope, reach DNA and change which genes a cell reads, the hypothesis offered for how a four-amino-acid molecule could push damaged lung tissue toward repair [3][6][12]. Bronchogen is the lung member of that set, and the work on it sits where peptide chemistry, lung biology and epigenetics meet [10][12].
Vladimir Khavinson, Galina Ryzhak, Evgeny Grigoriev and Irina Ryadnova at the St. Petersburg Institute of Bioregulation and Gerontology first synthesized the peptide and patented it in Europe in 2004, with priority on June 22; the patent was granted in 2008 [1]. They designed it to replace the polypeptide fractions that earlier work extracted from animal lungs and tracheae, preparations that were variable and carried a risk of allergic reaction [1]. The sources reviewed do not identify a parent protein for bronchogen; it is a designed compound with no structural analogue, and the natural preparations it replaced were tissue extracts rather than a single protein [1]. Its target tissue is the bronchial epithelium, the layer of cells that lines the airways and forms the first barrier between inhaled air and the body [1][8].
The research potential is concentrated on repair of the airway lining. In rats exposed to nitrogen dioxide for 60 days, a model of chronic obstructive pulmonary disease, a one-month course of bronchogen reversed the remodeling of the bronchial epithelium and lowered neutrophilic inflammation [8][9]. One Russian clinical study has tested it in 78 adults with chronic bronchitis, reporting improved symptoms and lung function without side effects [17]. As of October 2026, bronchogen has no FDA-approved product, no registered trial appears on ClinicalTrials.gov, and DailyMed lists no product carrying the name [14][18].
Key takeaways
- Bronchogen is a four-amino-acid synthetic peptide from the St. Petersburg peptide-bioregulator program, built as a lung-targeted signal with no parent protein behind it [1][12].
- In a rat model of obstructive lung disease, it restored the structure of the bronchial lining, raised local secretory immunoglobulin A and surfactant protein B, and reduced neutrophilic inflammation [8][9]. In rat fibrosis and hyperoxia models it limited structural damage [1].
- One 2014 Russian clinical study in 78 adults with chronic bronchitis reported improved symptoms and lung function and no side effects, but it was not placebo-controlled [17]. As of October 2026 the peptide has no FDA-approved product and no registered trial; neither the WADA nor the NCAA list names it, and both rely on catch-all language for unapproved and related substances [15][16][18].
How it works
DNA binding and the gene-expression hypothesis
The central claim is that bronchogen works inside the nucleus, the compartment that holds a cell's DNA. A gene is a stretch of DNA that a cell copies into RNA and then translates into protein, and transcription is that copying step. A promoter is the short DNA region in front of a gene where the copying machinery attaches, and methylation is a chemical mark added to a cytosine, one of the four DNA letters, that usually silences the gene beneath it. A peptide that binds DNA could change transcription without touching a receptor on the cell surface [3][7].
The biophysical work supports the first half of that idea. A differential scanning microcalorimeter measures the heat a sample absorbs as it warms, and the melting temperature it reports is the point at which half of a DNA double helix has come apart. In 2011 that instrument showed that bronchogen raised the melting temperature of calf thymus and mouse liver DNA by 3.1 degrees Celsius at a peptide-to-base-pair ratio between 0.01 and 0.055 [3]. The melting enthalpy, the total heat absorbed during separation, did not change, and the effect was the same for DNA rich in either base pair, so the peptide does not read a single base-pair code the way a transcription factor does [3]. The authors described the binding as strong and occasional, occurring on both strands and mainly at the nitrogen bases [3].
Later work added geometry and sequence preference. Spectrophotometry, viscometry and circular dichroism on DNA suggested a complex in which the peptide sits in the major groove, the wider of the two spiral channels on the DNA surface, near the guanine N7 site [7].
In HeLa cells, a human cervical cancer line used as a general model for cell biology, the labeled peptides epitalon, pinealon and testagen entered the cytoplasm, nucleus and nucleolus. Bronchogen itself was tested in solution, where it bound oligonucleotides containing CNG and CTG sequences in preference to other sequences and distinguished methylated from unmethylated cytosines [4]. Docking models built for 19 short peptides placed bronchogen on a ctcc sequence, the same site as the related kidney tripeptide Ovagen [6]. The computed site and the measured preference are not the same motif, which is one reason the binding model remains a hypothesis [4][6].
Tissue-specific gene regulation in bronchial cells
The second claim is that the binding changes gene activity in the right tissue and not elsewhere. Tissue specificity here means that a peptide affects bronchial cells more than pancreatic or skin cells, the property the inventors built the family around [5][12]. The evidence comes from human embryonic bronchial cell cultures grown through repeated passages, a standard way to age cells in a dish: late-passage cultures are older cells that have divided many times [5].
In those cultures, the differentiation markers CXCL12 and Hoxa3 fell with age, and bronchogen raised their expression; the effect was stronger in the aged cultures than in the young ones [5]. Differentiation is the process by which a stem-like cell acquires the specific job of its tissue, and a marker is a gene or protein used to recognize that state. The same study found the pancreatic peptide Pancragen acting on pancreatic cells and bronchogen acting on bronchial cells, each in its own tissue [5]. A 2020 review of the field lists bronchogen and Pancragen among the peptides that induce lung and pancreatic cell differentiation [13].
Methylation connects the DNA binding to that change in expression. In human bronchial epithelium cultures, the promoter methylation of NKX2-1 and SCGB1A1 changed with aging in step with their expression, and the authors proposed that these methylation changes might cause the age-related and peptide-induced shifts [10]. Other promoters, including FOXA2, stayed unmethylated in the bronchial cultures whatever the age or peptide exposure, so the effect is not a blanket change in methylation [10]. The same peptide also changed tobacco callus growth at concentrations from 10^-7 to 10^-9 molar, stimulating leaf formation and shifting the expression of CLE, KNOX1 and GRF genes, which are plant genes for peptide signals, developmental transcription factors and growth regulators [11]. A molecule that acts on both human bronchial cells and plant tissue is unlikely to do so through a single animal receptor, which is why the DNA route has stayed attractive [4][11].
The bronchial lining in obstructive lung disease
Chronic obstructive pulmonary disease, or COPD, is a long-term narrowing of the airways that makes breathing out difficult and damages the air sacs. In the rat model used here, nitrogen dioxide, a gas found in vehicle exhaust and cigarette smoke, is delivered intermittently for 60 days [8]. The resulting injury has three structural features the papers track: goblet cell hyperplasia, an overgrowth of the mucus-producing cells; squamous metaplasia, the replacement of the delicate ciliated lining with flatter, tougher cells; and emphysema, the destruction of alveolar walls that reduces the surface for gas exchange [8].
A one-month course of bronchogen in that model removed the signs of remodeling: goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema all fell, and ciliated cells came back [8]. Secretory immunoglobulin A, the antibody that guards mucosal surfaces, rose, and the cell mix and cytokine profile in bronchoalveolar lavage fluid, the fluid washed through the lungs to sample the air sacs, returned toward normal [8][9]. Surfactant protein B, which lowers surface tension so the alveoli do not collapse, also rose [9]. The authors read the combination as restored barrier and immune function [8][9].
The lavage data give the inflammatory detail. Neutrophils, the white blood cells that arrive first at an infected or irritated site, drive the inflammation in this model, and their activity fell and the cytokine and enzyme profile normalized with treatment [9]. The profile shifted away from the pro-inflammatory pattern, and local immunoglobulin A and surfactant protein B rose [9]. The abstracts report tissue structure and lavage chemistry, not a clinical endpoint such as survival or exercise capacity [8][9].
Concentration, target and what remains open
The amounts that work in these experiments are extremely low and the response is not simple. In organotypic lung culture, explants of lung tissue kept alive in a dish, 0.05 nanograms per milliliter stimulated growth in both 3-week-old and 18-month-old rats, and the patent reports activity from 1 to 10 nanograms per milliliter [1][2]. In plants the active range is 10^-7 to 10^-9 molar, and in the DNA experiments binding plateaus at a peptide-to-base-pair ratio near 0.055 [3][11]. That pattern is consistent with a saturable binding event.
No receptor for bronchogen has been identified in the sources reviewed, and no transcription factor has been shown to mediate its effects; the inventors' own account places the action on DNA rather than on a cell-surface protein [4][12]. That leaves several steps unproven: how the peptide crosses the membrane, how much reaches the nucleus, and whether the gene-expression changes cause the tissue effects or run alongside them [10][12]. The patent describes the compound as having no structural analogues, so there is no parent molecule whose known biology could fill the gap [1].
What has been studied in humans
As of October 2026, one clinical study of bronchogen has been published. It enrolled 78 adults with chronic bronchitis with an asthmatic component in remission and randomized them to standard therapy alone (20 patients) or standard therapy plus oral bronchogen for 30 days (58 patients) [17]. The paper reports that 86 percent of the treated group improved, with rises in vital capacity, total lung capacity and forced vital capacity of 13.2, 10.4 and 38.7 percent from baseline, and no side effects, complications, contraindications or drug dependence [17]. The control group improved only in forced vital capacity [17].
The study has limits. It was not placebo-controlled, blinding is not described, and the outcomes are largely subjective or spirometric, so the size of the effect is uncertain. It was published in the Russian journal Molecular Medicine, and no registration record appears on ClinicalTrials.gov [17][18].
The human cell data are separate. In cultures derived from human embryonic bronchial tissue, bronchogen raised the expression of CXCL12 and Hoxa3, two differentiation markers, and the rise was larger in late-passage cultures that had lower expression with age [5]. In the same cell system, the promoters of NKX2-1 and SCGB1A1 changed their methylation with aging in step with expression, and the authors proposed that these methylation changes might cause the age-related and peptide-induced shifts [10]. These are cultured cells, so they show what the peptide does to a cell's gene program and not what it does in a living airway.
The other human cell data come from a cervical cancer line used to study how short peptides enter cells. In HeLa cells, labeled epitalon, pinealon and testagen reached the cytoplasm, nucleus and nucleolus, while bronchogen was tested in solution for DNA binding with a sequence preference [4]. HeLa cells are not lung cells, and the uptake experiment did not test bronchogen, so it shows that related short peptides can reach a human nucleus, not that bronchogen does so in the bronchial lining.
No human pharmacokinetic study has been published, so how much of an administered amount reaches the lung, how long it stays and what it does to immune surveillance in a living patient are all unmeasured [1][17]. The animal work described below carries the rest of the efficacy record.
Doses studied in human trials
As of October 2026, Bronchogen remains without an FDA-approved product and has no registered clinical trial. The regimens below are those reported in the cited human and animal studies.
0.2 micrograms per kilogram intraperitoneally in the lung-injury models; 1 to 5 milligrams per kilogram once intramuscularly in the mouse toxicity study; 1 microgram to 1 milligram per kilogram daily in the 90-day rat and 6-month guinea pig studies
White mongrel rats (96 to 120 per injury model), 60 mice in the acute toxicity study, 60 rats in the 90-day study and 100 guinea pigs in the 6-month study
0.1 mg per capsule, 2 capsules twice daily for 30 days, added to standard therapy
78 adults with chronic bronchitis with an asthmatic component in remission, aged 34 to 65 (44 women, 34 men); 58 in the bronchogen group and 20 controls
Lab and animal studies
The animal record is built around induced lung injury, and most of it comes from the patent and from one St. Petersburg group. The patent describes acute bacterial pneumonia in rats, bleomycin-induced lung fibrosis, sublethal hyperoxic injury and organotypic lung culture, each with a control group and each reported as improved by the tetrapeptide [1]. The two COPD papers apply the same logic to a nitrogen dioxide model [8][9].
The pneumonia experiments used 120 rats infected intratracheally with Staphylococcus aureus after a cold exposure, with treatment starting two days later at 0.2 micrograms per kilogram intraperitoneally for seven days [1]. Mortality in the first 48 hours was about 20 percent, and treated animals had more alveolar macrophages and higher phagocytic activity from day 3 to day 10 [1]. In the hyperoxic model, the phagocytic index on days 10 and 20 was 50.8 and 45.5 in treated rats against 27.3 and 26.4 in controls [1].
Bleomycin fibrosis is the strongest structural result. Rats given three intratracheal doses of bleomycin two weeks apart developed interstitial fibrosis, and by day 60 the control group had a ventricular index of 66.2 percent, a sign of right-heart hypertrophy from lung disease [1]. Treated rats reached 46.6 percent, and their lavage lymphocyte counts were lower on days 30 and 60 [1]. The peptide did not prevent fibrosis completely, and the patent says the morphological changes were less pronounced than in controls [1].
The COPD model gives the most detailed picture of the airway lining. Sixty days of intermittent nitrogen dioxide produced goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema, and one month of treatment reversed each of them and restored ciliated cells [8]. Lavage fluid from treated animals had lower neutrophilic inflammation, a normalized cytokine and enzyme profile, and higher secretory immunoglobulin A and surfactant protein B [9]. Both abstracts describe structure and lavage chemistry, and neither reports a functional outcome such as exercise capacity or survival [8][9].
The DNA work comes from a different set of laboratories: calorimetry on calf thymus and mouse liver DNA showed a 3.1 degree Celsius rise in melting temperature, no change in melting enthalpy and no base-pair preference, which the authors read as strong binding at scattered sites on both strands [3]. A 2014 study using spectrophotometry, viscometry and circular dichroism placed the peptide in the major groove near guanine N7 [7]. Docking models for 19 short peptides assigned bronchogen and Ovagen to a ctcc site [6]. In cells, labeled epitalon, pinealon and testagen reached the nucleus and nucleolus, while bronchogen bound CNG and CTG sequences in solution [4]. The purified-DNA and docking experiments do not show a change in transcription; the gene-expression evidence comes from the cell-culture work that follows.
That cell-culture work gives the functional readout. Human embryonic bronchial cultures showed lower CXCL12 and Hoxa3 expression with repeated passage, and bronchogen raised it, more so in the older cultures [5]. Promoter methylation of NKX2-1 and SCGB1A1 tracked expression across culture age, while FOXA2 stayed unmethylated in the bronchial cells throughout [10]. The same peptide acted on tobacco callus at 10^-7 to 10^-9 molar, changing growth, leaf formation and the expression of CLE, KNOX1 and GRF genes [11]. A 2021 systematic review collects this literature and lists bronchogen as a DNA-binding regulator of lung cell function and differentiation [12], and a 2020 review of peptide-driven differentiation groups it with Pancragen as an inducer of lung cell differentiation [13].
The toxicology is confined to the patent. A single intramuscular injection of 1 to 5 milligrams per kilogram in 60 mice, described as up to 5,000 times the intended therapeutic amount, produced no toxic reactions [1]. Rats given 1 microgram per kilogram to 1 milligram per kilogram daily for 90 days showed no side effects in the patent's subacute study [1]. At the lowest dose tested, 1 microgram per kilogram daily for 6 months, guinea pigs had a leukocyte count of 11.4 against 8.9 times 10^9 per liter in controls, while other blood indices did not change significantly [1]. The patent describes no carcinogenicity, reproductive, genotoxicity or pharmacokinetic study [1].
Research in detail
Patent with preclinical examples: rat models of acute bacterial pneumonia, bleomycin-induced lung fibrosis and hyperoxic lung injury, rat lung explant culture, and acute, subacute and chronic toxicology in mice, rats and guinea pigs · White mongrel rats (96 to 120 per injury model), 60 mice in the acute toxicity study, 60 rats in the 90-day study and 100 guinea pigs in the 6-month study
Treated rats recovered faster from bacterial pneumonia and showed higher alveolar macrophage phagocytosis, less right-heart hypertrophy after bleomycin, and better preservation of lung structure after hyperoxia. Mice and rats showed no toxic reactions, and guinea pigs had a small rise in white blood cell count at 6 months.
Evidence scope: Single patent from one institution, not peer reviewed; no independent replication, and no human data in the patent. Group sizes and p-values appear in the patent text and tables.
Rat model of COPD induced by intermittent nitrogen dioxide, with one month of peptide treatment · Rats exposed to nitrogen dioxide for 60 days and treated with bronchogen for one month
Bronchogen removed the signs of airway remodeling, including goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema, restored ciliated cells, raised secretory immunoglobulin A, and normalized the cell mix and pro-inflammatory cytokine profile in the bronchoalveolar space.
Evidence scope: Animal model of a single induced injury; the abstract does not state the peptide amount, the number of animals per group or the statistical methods. Abstract reviewed; full text not read.
Rat model of COPD induced by intermittent nitrogen dioxide, with analysis of bronchoalveolar lavage fluid · Rats with nitrogen dioxide-induced COPD after a course of peptide treatment
After the treatment course, neutrophilic inflammation fell, the cell composition and cytokine-enzyme profile of lavage fluid normalized, and secretory immunoglobulin A and surfactant protein B rose while the bronchial epithelium recovered its structure.
Evidence scope: Animal model; the abstract gives no peptide amount, group size or statistics, and the paper shares authors with the 2015 study. Abstract reviewed; full text not read.
Organotypic tissue culture of explants from four organs, with and without peptide, in young and aged rats · Lung, heart, prostate and pancreas explants from 3-week-old and 18-month-old rats
At 0.05 nanograms per milliliter, each peptide stimulated growth of its matching tissue in both age groups, and bronchogen acted on lung explants.
Evidence scope: Abstract only; the paper reports tissue outgrowth as the endpoint, with no mechanism and no measure of peptide uptake. Full text not read.
Human cell culture study across passage number, with peptide treatment and expression measurement · Human embryonic pancreatic and bronchial cell cultures, plus human prostatic fibroblasts
Late-passage bronchial cultures had lower CXCL12 and Hoxa3 expression, and bronchogen raised it, with a larger effect in the aged cultures. Pancragen acted on pancreatic cells and vesugen on fibroblasts.
Evidence scope: Cultured embryonic cells rather than adult tissue; expression of two markers is a narrow readout, and the abstract does not report peptide concentrations. Abstract reviewed; full text not read.
Human cell culture study comparing promoter methylation and gene expression across culture age, with and without peptide · Human pancreatic and bronchial epithelium cell cultures
Promoter methylation of NKX2-1 and SCGB1A1 in bronchial cells changed with aging in step with expression, and the authors proposed that these marks might explain the age-related and peptide-induced shifts. FOXA2 stayed unmethylated in the bronchial cells regardless of age or peptide.
Evidence scope: Correlation between methylation and expression rather than a demonstrated causal chain; cultured cells, and the abstract does not give peptide concentrations. Abstract reviewed; full text not read.
Differential scanning microcalorimetry of DNA with graded peptide concentrations · Calf thymus and mouse liver DNA in solution
Bronchogen raised the DNA melting temperature by 3.1 degrees Celsius at a peptide-to-base-pair ratio from 0.01 to 0.055, left the melting enthalpy unchanged, and showed no preference for adenine-thymine or guanine-cytosine rich DNA. The authors described binding to both strands, mainly at the nitrogen bases.
Evidence scope: Purified DNA in solution, with no chromatin, histones or living cells; the model cannot show which genes would be affected. Abstract reviewed; full text not read.
Fluorescence microscopy of labeled peptide in cultured cells, plus fluorescence quenching assays with oligonucleotides · HeLa cells and synthetic single- and double-stranded oligonucleotides
Labeled epitalon, pinealon and testagen entered the cytoplasm, nucleus and nucleolus of HeLa cells. In the DNA-binding assays bronchogen preferred CNG-containing oligonucleotides, with a further preference for CTG, and the peptides distinguished cytosine methylation.
Evidence scope: Cancer cell line rather than airway cells; the labeled-peptide uptake experiments named epitalon, pinealon and testagen, not bronchogen, and binding preferences in a cuvette need not match binding in chromatin. Abstract reviewed; full text not read.
Randomized controlled clinical study of oral bronchogen added to standard therapy for 30 days, with a laboratory cell-culture component · 78 adults with chronic bronchitis with an asthmatic component in remission, aged 34 to 65 (44 women, 34 men); 58 in the bronchogen group and 20 controls
86 percent of treated patients reported improved well-being, fewer cough and dyspnea attacks and less sputum, and vital capacity, total lung capacity and forced vital capacity rose by 13.2, 10.4 and 38.7 percent from baseline. Controls improved only in forced vital capacity, and no side effects, complications, contraindications or drug dependence were reported.
Evidence scope: Not placebo-controlled and no blinding is described; one St. Petersburg research group; published in a Russian journal; the article is not indexed in PubMed. Full text read (Russian).
History and where it stands today
Bronchogen was designed to replace the tissue extracts used for lung disease, and it became a patented tetrapeptide with a small laboratory literature and one small clinical study, but never a registered human trial.
- 2004Khavinson and colleagues file the European patent on the tetrapeptide, with priority on June 22, and report rat models of bacterial pneumonia, bleomycin fibrosis and hyperoxic injury plus toxicology in mice, rats and guinea pigs [1].
- 2006The peptide, now named bronchogen, stimulates lung explants from young and aged rats at 0.05 nanograms per milliliter, alongside cardiogen, prostamax and pancragen in their matching tissues [2].
- 2011Two papers describe DNA binding: calorimetry shows a 3.1 degree Celsius rise in melting temperature, and a HeLa study reports nuclear entry by labeled short peptides while bronchogen binds CNG and CTG sequences in solution [3][4].
- 2012Bronchogen raises CXCL12 and Hoxa3 expression in aging human bronchial cell cultures, with a larger effect in late-passage cells [5].
- 2014A human bronchial cell study places the peptide in the DNA major groove and ties it to gene regulation, and a clinical paper reports a study of 78 adults with chronic bronchitis, 58 of them treated with oral bronchogen [7][17].
- 2015A rat COPD model shows reversal of goblet cell hyperplasia, squamous metaplasia and emphysema after one month of treatment, and a separate paper ties bronchial gene expression to promoter methylation [8][10].
- 2017The anti-inflammatory and regenerative results in the same COPD model appear in a Russian physiology journal, and a tobacco study shows it changing callus growth and plant gene expression [9][11].
- 2021A systematic review of peptide gene regulation lists bronchogen as a DNA-binding regulator of lung cell function and differentiation [12].
- December 2024The European patent's 20-year term ends in December 2024 [1].
- October 2026As of October 2026, bronchogen has no FDA-approved product and no registered trial [14][18]. The WADA 2026 list does not name it; S0 covers substances without governmental approval for human use [15]. The NCAA 2026-27 list does not name it either, and its class 6 covers related peptide hormones and mimetics; see the NCAA page [16].
How it compares with related peptides
Epitalon is a well-known peptide from the same institute, a four-amino-acid molecule studied for neuro-immuno-endocrine and geroprotective effects [12]. The 2021 systematic review lists both compounds in one table of short peptides, describing epitalon as a DNA binder with wide systemic effects and bronchogen as a regulator of lung cell function and differentiation [12]. The chemistry of the approach is shared, and the difference is the tissue each peptide was designed to address [12][13].
Cardiogen is the heart member of the same peptide set. The 2006 organotypic study grew heart and lung explants in the same experiment and found each peptide active in its matching tissue at 0.05 nanograms per milliliter, a direct demonstration of the tissue-specific claim [2]. Cardiogen is studied for cardiac tissue, bronchogen for the airway lining.
Pancragen is the pancreas member, and the 2012 differentiation study ran it on pancreatic cells while bronchogen ran on bronchial cells in the same experiment [5]. Both raised tissue-specific differentiation markers in aging cultures, and the pancreatic peptide acted on pancreatic cells in that experiment, which is the result the family's tissue-specificity argument rests on [5][13].
Side effects and safety signals
The safety record is animal toxicology plus one short human trial, and most of it comes from the patent that introduced the peptide.
- One clinical study in 78 adults with chronic bronchitis reported no side effects, complications, contraindications or drug dependence during 30 days of oral bronchogen added to standard therapy [17].
- The trial was not designed as a safety study, was not placebo-controlled, and followed patients for one month, so it does not establish tolerability beyond that short course [17].
- A single intramuscular injection of 1 to 5 milligrams per kilogram in 60 mice, described by the inventors as up to 5,000 times the intended therapeutic amount, produced no toxic reactions [1].
- Rats given 1 microgram per kilogram to 1 milligram per kilogram daily for 90 days showed no side effects in the patent's subacute study [1].
- At the lowest dose tested, 1 microgram per kilogram daily for 6 months, guinea pigs had a leukocyte count of 11.4 against 8.9 times 10^9 per liter, while red cell, platelet, sedimentation and serum biochemistry indices did not change significantly [1].
- The toxicology is patent-only and has not been peer reviewed, and the patent describes no carcinogenicity, reproductive or genotoxicity study [1].
- No pharmacokinetic study in any species is described, so how much peptide reaches the lung after a given amount is unmeasured [1][17].
- Identity and purity of any research supply rest on the certificate of analysis, and the COA library collects those documents for comparison.
The future: what's next for Bronchogen
There is no registered trial to track. A ClinicalTrials.gov search on October 23, 2026 returned no study using bronchogen as an intervention, and DailyMed lists no product [14][18]. No registration record for the 2014 clinical study appears on ClinicalTrials.gov, so no scheduled regulatory decision appears in the sources reviewed [17][18].
The European patent's 20-year term ended in December 2024. The lung-injury package is thin by modern standards: one institution's models, no pharmacokinetics, no carcinogenicity or reproductive toxicology, and no independent replication of the COPD results [1][8][9].
The mechanism work is where the research is most likely to continue. The DNA-binding measurements, the sequence preferences and the methylation data together suggest a testable route, and the plant experiments show that the peptide acts on cells from another kingdom, which argues for a general nucleic-acid mechanism rather than a lung receptor [4][10][11]. A chromatin-based experiment that measures transcription after peptide exposure would settle whether binding changes gene output [3][4].
The COPD model also needs repetition outside the group that built it. Both papers share authors from the same St. Petersburg research group, and neither abstract reports a functional endpoint such as exercise capacity or survival [8][9]. Replication with a functional readout, and a dose-ranging design, would show whether the structural recovery changes how the lungs work.
- Whether the structural recovery seen in rats with nitrogen dioxide injury explains the spirometry changes reported in the 2014 clinical study, and whether a placebo-controlled trial confirms a functional benefit [9][17].
- What the peptide actually binds inside a cell, since no receptor has been identified and the DNA interaction has been studied only in purified systems and cell lines [3][4].
- Whether the changes in gene expression cause the tissue repair or follow it, which would need a transcription-level experiment rather than marker expression alone [10][13].
- How much peptide reaches the bronchial lining after any route of administration, because no pharmacokinetic study in any species has been published [1].
- Whether repeated exposure in humans raises an immune response, which neither the animal toxicology nor the 2014 clinical study measured [1][17].